A Multicenter Trial of Oral Zidovudine in Children with Advanced Human Immunodeficiency Virus Disease
1991; Massachusetts Medical Society; Volume: 324; Issue: 15 Linguagem: Inglês
10.1056/nejm199104113241503
ISSN1533-4406
AutoresRoss E. McKinney, Mary Maha, Edward M. Connor, Judith Feinberg, Gwendolyn B. Scott, Michael Wulfsohn, Kenneth McIntosh, William Borkowsky, John F. Modlin, Peggy Sue Weintrub, Karen O’Donnell, Richard D. Gelber, Gail Knowlton Rogers, Sandra Nusinoff Lehrman, Catherine M. Wilfert,
Tópico(s)HIV/AIDS drug development and treatment
ResumoZidovudine has been shown to be an effective antiretroviral treatment in adults with human immunodeficiency virus (HIV) infection. We examined the safety of zidovudine and the tolerance of and therapeutic response to the drug in 88 children with advanced HIV disease. During a 24-week outpatient trial, zidovudine (180 mg per square meter of body-surface area per dose) was given by mouth every six hours and serial measurements were made of clinical, immunologic, and virologic indexes. Children who completed 24 weeks of treatment were permitted to continue receiving zidovudine.
Referência(s)